All In Biotech

Drug Trial Radar · NCT01467362

Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension.

Last checked: Nov 19, 2026Latest source record: Feb 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Nov 2011

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Nov 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local, immunological, genetic and environmental factors. Important symptoms of atopic dermatitis are dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is associated with skin barrier dysfunction that facilitates an easier allergen penetration into the skin with an increased irritation and subsequent cutaneous inflammation. A lack of important stratum corneum intercellular lipids and an inadequate ratio between compounds enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy usually twice daily improves dryness and subsequently pruritus during the treatment of atopic dermatitis and especially improves the barrier function. Emollients make part of basic therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology and Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier alteration, measured by skin hydration, is a key element for evaluation of emollient treatment efficacy. The primary objective of this study is to demonstrate the efficacy of the tested product (V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient formula during 28 days.

Conditions

  • Atopic Dermatitis

Interventions

  • V0034CR01BDrug

    Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days

  • Vehicle creamDrug

    Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days

  • desonide 0.1% creamDrug

    cream, once a day (in the evening) during flares

  • Foaming gelOther

    for the washing and cleaning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Xerosis score: mean evolution over the different time-points of double-blind periodTime frame: During 28 days (Day 1, Day 7, Day 14, Day 21 and Day 28)

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Estonia

    Tallinn, Estonia

  • Estonia

    Tartu, Estonia

  • France

    Bordeaux, France

  • France

    Martigues, France

  • France

    Nantes, France

  • France

    Nice, France

  • France

    Poitiers, France

  • Lithuania

    Vilnius, Lithuania

  • Poland

    Bialystok, Poland

  • Poland

    Inowrocław, Poland

  • Poland

    Lodz, Poland

  • Poland

    Oleśnica, Poland

  • Poland

    Płock, Poland

  • Poland

    Poznan, Poland

  • Poland

    Strzelce Opolskie, Poland

  • Poland

    Warsaw, Poland

  • Poland

    Żyrardów, Poland

  • Romania

    Brasov, Romania

  • Romania

    Bucharest, Romania

  • Romania

    Constanța, Romania

  • Romania

    Craiova, Romania

  • Romania

    Iași, Romania

  • Romania

    Ploieşti, Romania

  • Romania

    Sibiu, Romania

  • Romania

    Târgu Mureş, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.